|
1
|
Mundy GR: Metastasis to bone: Causes,
consequences and therapeutic opportunities. Nat Rev Cancer.
2:584–593. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coleman RE: Clinical features of
metastatic bone disease and risk of skeletal morbidity. Clin Cancer
Res. 12:6243s–6249s. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brodowicz T, O'Byrne K and Manegold C:
Bone matters in lung cancer. Ann Oncol. 23:2215–2222. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roodman GD: Mechanisms of bone metastasis.
N Engl J Med. 350:1655–1664. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Serafini AN: Therapy of metastatic bone
pain. J Nucl Med. 42:895–906. 2001.PubMed/NCBI
|
|
6
|
Rosen LS, Gordon D, Tchekmedyian NS,
Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng
M, Urbanowitz G, et al: Long-term efficacy and safety of zoledronic
acid in the treatment of skeletal metastases in patients with
nonsmall cell lung carcinoma and other solid tumors: A randomized,
Phase III, double-blind, placebo-controlled trial. Cancer.
100:2613–2621. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zarogoulidis K, Boutsikou E, Zarogoulidis
P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, Tzanakakis G,
Kanakis I and Karamanos NK: The impact of zoledronic acid therapy
in survival of lung cancer patients with bone metastasis. Int J
Cancer. 125:1705–1709. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De Castro J, García R, Garrido P, Isla D,
Massuti B, Blanca B and Vázquez J: Therapeutic potential of
denosumab in patients with lung cancer: Beyond prevention of
skeletal complications. Clin Lung Cancer. 16:431–446. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Scagliotti GV, Hirsh V, Siena S, Henry DH,
Woll PJ, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M,
Mehta ND, et al: Overall survival improvement in patients with lung
cancer and bone metastases treated with denosumab versus zoledronic
acid: Subgroup analysis from a randomized phase 3 study. J Thorac
Oncol. 7:1823–1829. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Katakami N, Kunikane H, Takeda K, Takayama
K, Sawa T, Saito H, Harada M, Yokota S, Ando K, Saito Y, et al:
Prospective study on the incidence of bone metastasis (BM) and
skeletal-related events (SREs) in patients (pts) with stage IIIB
and IV lung cancer-CSP-HOR 13. J Thorac Oncol. 9:231–238. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kang EJ, Lee SY, Kim HJ, Min KH, Hur GY,
Shim JJ, Kang KH, Oh SC, Seo JH, Lee SY and Kim JS: Prognostic
factors and skeletal-related events in patients with small cell
lung cancer with bone metastases at the time of diagnosis.
Oncology. 90:103–111. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cetin K, Christiansen CF, Jacobsen JB,
Nørgaard M and Sørensen HT: Bone metastasis, skeletal-related
events, and mortality in lung cancer patients: A Danish
population-based cohort study. Lung Cancer. 86:247–254. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ren Y, Dai C, Zheng H, Zhou F, She Y,
Jiang G, Fei K, Yang P, Xie D and Chen C: Prognostic effect of
liver metastasis in lung cancer patients with distant metastasis.
Oncotarget. 7:53245–53253. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ogino H, Hanibuchi M, Kakiuchi S, Saijo A,
Tezuka T, Toyoda Y, Tobiume M, Otsuka K, Sakaguchi S, Goto H, et
al: Analysis of the prognostic factors of extensive disease
small-cell lung cancer patients in Tokushima University Hospital. J
Med Invest. 63:286–293. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goldhirsch A, Joss R, Cavalli F and
Brunner KW: Etoposide as single agent and in combination
chemotherapy of bronchogenic carcinoma. Cancer Treat Rev. 9:85–90.
1982. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Evans WK, Osoba D, Feld R, Shepherd FA,
Bazos MJ and DeBoer G: Etoposide (VP-16) and cisplatin: An
effective treatment for relapse in small-cell lung cancer. J Clin
Oncol. 3:65–71. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Matsumoto S, Kimura S, Segawa H, Kuroda J,
Yuasa T, Sato K, Nogawa M, Tanaka F, Maekawa T and Wada H: Efficacy
of the third-generation bisphosphonate, zoledronic acid alone and
combined with anti-cancer agents against small cell lung cancer
cell lines. Lung Cancer. 47:31–39. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kenessey I, Kói K, Horváth O, Cserepes M,
Molnár D, Izsák V, Dobos J, Hegedűs B, Tóvári J and Tímár J:
KRAS-mutation status dependent effect of zoledronic acid in human
non-small cell cancer preclinical models. Oncotarget.
7:79503–79514. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Neville-Webbe HL, Evans CA, Coleman RE and
Holen I: Mechanisms of the synergistic interaction between the
bisphosphonate zoledronic acid and the chemotherapy agent
paclitaxel in breast cancer cells in vitro. Tumour Biol. 27:92–103.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ozturk OH, Bozcuk H, Burgucu D, Ekinci D,
Ozdogan M, Akca S and Yildiz M: Cisplatin cytotoxicity is enhanced
with zoledronic acid in A549 lung cancer cell line: Preliminary
results of an in vitro study. Cell Biol Int. 31:1069–1071. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Budman DR and Calabro A: Zoledronic acid
(Zometa) enhances the cytotoxic effect of gemcitabine and
fluvastatin: In vitro isobologram studies with conventional and
nonconventional cytotoxic agents. Oncology. 70:147–153. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fournier PG, Chirgwin JM and Guise TA: New
insights into the role of T cells in the vicious cycle of bone
metastases. Curr Opin Rheumatol. 18:396–404. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peng X, Guo W, Ren T, Lou Z, Lu X, Zhang
S, Lu Q and Sun Y: Differential expression of the RANKL/RANK/OPG
system is associated with bone metastasis in human non-small cell
lung cancer. PLoS One. 8:e583612013. View Article : Google Scholar : PubMed/NCBI
|
